down arrow

Replimune Group, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US76029N1063
USD
10.53
0.53 (5.3%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

10.0310.56

52 Week

2.6814.80
Valuation
Technical
Day's Volume

CASH

1.31 M

Shareholding (Mar 2025)

FII

19.10%

Held by 102 FIIs

DII

30.13%

Held by 45 DIIs

Promoter

16.59%

How big is Replimune Group, Inc.?

22-Jun-2025

As of Jun 18, Replimune Group, Inc. has a market capitalization of 732.71 million and reported net sales of 0.00 million with a net profit of -247.29 million over the latest four quarters. Shareholder's funds are 415.84 million, and total assets amount to 551.33 million.

As of Jun 18, Replimune Group, Inc. has a market capitalization of 732.71 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 0.00 million for the latest four quarters, with a net profit of -247.29 million during the same period.<BR><BR>As of Mar 25, the balance sheet shows shareholder's funds of 415.84 million and total assets amounting to 551.33 million.

Read More

What does Replimune Group, Inc. do?

22-Jun-2025

Replimune Group, Inc. is a clinical-stage biotechnology company focused on oncolytic immunotherapy for cancer treatment, with a market cap of approximately $732.71 million and a recent net profit loss of $74 million. The company has no dividend yield and negative return on equity.

Overview: <BR>Replimune Group, Inc. is a clinical-stage biotechnology company engaged in oncolytic immunotherapy to treat cancer patients, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -74 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 732.71 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.04 <BR>Return on Equity: -59.47% <BR>Price to Book: 1.76<BR><BR>Contact Details: <BR>Address: 500 Unicorn Park Dr, WOBURN MA: 01801-3377 <BR>Tel: ['1 781 2229600', '1 339 9702843'] <BR>Fax: 1 302 6555049 <BR>Website: https://www.replimune.com/

Read More

Who are in the management team of Replimune Group, Inc.?

22-Jun-2025

As of March 2022, the management team of Replimune Group, Inc. includes Mr. Dieter Weinand (Independent Chairman), Dr. Robert Coffin (President and Chief R&D Officer), and Mr. Philip Astley-Sparke (CEO). The Board also features independent directors such as Dr. Kapil Dhingra and Dr. Hyam Levitsky.

As of March 2022, the management team of Replimune Group, Inc. includes the following individuals:<BR><BR>- Mr. Dieter Weinand, Independent Chairman of the Board<BR>- Dr. Robert Coffin, President, Director, Chief Research & Development Officer<BR>- Mr. Philip Astley-Sparke, Chief Executive Officer, Director<BR><BR>Additionally, the Board of Directors features several independent directors: Dr. Kapil Dhingra, Dr. Hyam Levitsky, Ms. Tanya Lewis, Mr. Paolo Pucci, and Mr. Jason Rhodes.

Read More

Is Replimune Group, Inc. technically bullish or bearish?

20-Sep-2025

As of September 5, 2025, Replimune Group, Inc. exhibits a bearish trend supported by negative MACD signals, bearish moving averages, and significant underperformance compared to the S&P 500, with year-to-date returns of -71.43% versus the S&P 500's 12.22%.

As of 5 September 2025, the technical trend for Replimune Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The Bollinger Bands and KST also confirm a bearish outlook on both weekly and monthly time frames. Daily moving averages are bearish, further supporting this bearish sentiment. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. <BR><BR>In terms of performance, Replimune has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.43% compared to the S&P 500's 12.22%, and a one-year return of -68.77% versus the S&P 500's 17.14%. Overall, the technical indicators strongly suggest a bearish outlook for the stock.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 471 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.05

stock-summary
Return on Equity

-83.22%

stock-summary
Price to Book

1.40

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-87 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
78.63%
0%
78.63%
6 Months
9.35%
0%
9.35%
1 Year
-19.86%
0%
-19.86%
2 Years
-10.08%
0%
-10.08%
3 Years
-48.18%
0%
-48.18%
4 Years
-61.93%
0%
-61.93%
5 Years
-76.67%
0%
-76.67%

Replimune Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Replimune Group, Inc. technically bullish or bearish?

As of 5 September 2025, the technical trend for Replimune Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from the weekly and monthly MACD, both showing bearish signals. The Bollinger Bands and KST also confirm a bearish outlook on both weekly and monthly time frames. Daily moving averages are bearish, further supporting this bearish sentiment. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. In terms of performance, Replimune has significantly underperformed the S&P 500 across multiple periods, with a year-to-date return of -71.43% compared to the S&P 500's 12.22%, and a one-year return of -68.77% versus the S&P 500's 17.14%. Overall, the technical indicators strongly suggest a bearish outlook for the stock....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-219.45%
EBIT to Interest (avg)
-34.05
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.04
Sales to Capital Employed (avg)
0
Tax Ratio
0.52%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.92
EV to EBIT
-1.39
EV to EBITDA
-1.41
EV to Capital Employed
-20.84
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-59.47%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 59 Schemes (34.18%)

Foreign Institutions

Held by 102 Foreign Institutions (19.1%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -61.15% vs -8.47% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-89.20",
          "val2": "-57.10",
          "chgp": "-56.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "2.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-86.70",
          "val2": "-53.80",
          "chgp": "-61.15%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is -14.60% vs -23.81% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-259.90",
          "val2": "-234.00",
          "chgp": "-11.07%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "7.90",
          "val2": "6.70",
          "chgp": "17.91%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-247.30",
          "val2": "-215.80",
          "chgp": "-14.60%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-89.20
-57.10
-56.22%
Interest
2.00
2.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-86.70
-53.80
-61.15%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -61.15% vs -8.47% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Mar'25stock-summary
Mar'25
Mar'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-259.90
-234.00
-11.07%
Interest
7.90
6.70
17.91%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-247.30
-215.80
-14.60%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Mar 2025 is 0.00% vs 0.00% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is -14.60% vs -23.81% in Mar 2024

All Annual Resultsstock-summary
stock-summaryCompany CV
About Replimune Group, Inc. stock-summary
stock-summary
Replimune Group, Inc.
Pharmaceuticals & Biotechnology
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Company Coordinates stock-summary
Company Details
500 Unicorn Park Dr , WOBURN MA : 01801-3377
stock-summary
Tel: 1 781 22296001 339 9702843
stock-summary
https://www.replimune.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."